Flushed with recent clinical trial wins, Apellis has moved quickly ahead with an initial public offering.

Shanghai-based biotech EOC Pharma has raised $32 million from Chinese investors to help it bring a series of cancer drugs to market.

We kick off a new long form series assessing the life science industry from its leaders with ex-Teva chief Jeremy Levin.

Aimmune chief Stephen Dilly, M.B.B.S., Ph.D., is calling it a day.

Following poor results from Roche and AstraZeneca, Sanofi says it is canning a phase 2 trial in idiopathic pulmonary fibrosis.

Five Prime Therapeutics has tapped into its existing management to replace current president and CEO Rusty Williams.

Forge Therapeutics and Evotec have launched a discovery platform to develop novel antibiotics targeting metalloenzymes.

Around a third of Trevena’s workforce are facing the ax as the biotech throws all its weight behind soon-to-be-filed injectable pain therapy Olinvo.

Just months after its $80 million IPO, AnaptysBio is looking to raise another block of cash and accelerate development of its lead drug for eczema.